AGP Executive Report
Last update: 3 hours agoHepatitis B Breakthrough: GSK’s experimental antiviral bepirovirsen showed a “functional cure” in nearly 20% of chronic hepatitis B patients after six months, with Phase III results presented at EASL 2026 and an FDA submission expected this fall. Cancer Update: Johnson & Johnson reported updated CHRYSALIS-2 data: RYBREVANT® (amivantamab) + LAZCLUZE® (lazertinib) reached nearly 3.5 years median overall survival in first-line atypical EGFR-mutated non-small cell lung cancer, with consistent responses across subgroups. Ebola Screening Tightened (US): The US Embassy in Singapore updated rules for travellers with recent presence in DRC, Uganda, or South Sudan, requiring designated-airport arrival for enhanced Ebola screening. Dental Cost Pressure: A Singapore report highlights how private dental care can quickly become unaffordable for younger adults, with one case topping S$1,800 and wiping out MediSave. CPF Stability: CPF interest rates for July–Sept 2026 will stay unchanged: OA 2.5%, and SMRA 4%, plus HDB concessionary loan 2.6%. Food & Wellness for Kids: A student care programme in Sengkang spotlights in-house, additive-free meal planning to support energy and focus during long after-school routines.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
